Stock Events

Stock Events

Gubra AS 

€40.00
88
+€0.56+1.42% 13:53 Today

Statistics

Day High
40.36
Day Low
40
52W High
44
52W Low
38.4
Volume
1
Avg. Volume
-
Mkt Cap
657.44M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Jul 2025
€8.20
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

Aug 20Expected
Q2 2026
-0.87
-0.81
-0.74
-0.67
Expected EPS
-0.67028494848
Actual EPS
-0.8743697625599999

Financials

64.12%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
353.41MRevenue
226.61MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PI3.XETRA. It's not an investment recommendation.
Novo Nordisk
19
NOVO-B.CO
NVIDIA
10
NVDA
Torm
9
TRMD-A.CO
Danske Bank AS
9
DANSKE.CO

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novo Nordisk
NVO
Mkt Cap176.43B
Novo Nordisk is a leading global healthcare company specializing in diabetes care, which directly competes with Gubra's focus on obesity and diabetes research.
Lilly(Eli) &
LLY
Mkt Cap1.26T
Eli Lilly is a major player in the pharmaceutical industry with significant investments in diabetes and metabolic disorders, overlapping with Gubra's research areas.
Sanofi
SNY
Mkt Cap106.24B
Sanofi operates globally in the pharmaceutical sector, focusing on chronic diseases including diabetes, competing in the same therapeutic areas as Gubra.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca actively develops treatments for various metabolic disorders, including diabetes, positioning it as a competitor in the same field as Gubra.
Merck
MRK
Mkt Cap368.89B
Merck is known for its strong portfolio in diabetes care and treatment, making it a direct competitor to Gubra's diabetes-related projects.
Bristol-Myers Squibb
BMY
Mkt Cap127.71B
Bristol-Myers Squibb, with its broad range of biopharmaceutical products, competes in the metabolic disease sector, relevant to Gubra's focus areas.
Pfizer
PFE
Mkt Cap173.95B
Pfizer has a diverse portfolio that includes treatments for metabolic disorders and diabetes, competing with Gubra in these healthcare segments.
Roche
RHHBY
Mkt Cap334.28B
Roche, with its extensive research and development in diabetes management and other metabolic disorders, is a competitor in the same scientific space as Gubra.
Takeda Pharmaceutical
TAK
Mkt Cap66.81B
Takeda focuses on lifestyle and chronic diseases, including diabetes, which aligns them as competitors with Gubra in the field of metabolic health research.

About

Gubra A/S is a biotechnology firm engaged in two core activities: offering contract research organization (CRO) services for pre-clinical development, and advancing its own internal early-stage drug and target discovery initiatives. Its CRO division provides specialized pre-clinical research and development support to companies in the pharmaceutical and biotechnology sectors. These services encompass a wide range of capabilities, including in vivo pharmacology, tissue analysis, various assay development, molecular pharmacology, bioanalytical testing, next-generation sequencing (NGS), and both two-dimensional and three-dimensional imaging techniques. Established in 2008, the company has its headquarters in Horsholm, Denmark.
Show More
CEO
Markus Rohrwild
Employees
330
Country
Denmark
ISIN
DK0062266474
WKN
000A3D9NV

Listings

STU
DE
PI3.STU
MU
DE
PI3.MU
OTC Link
US
GUBRF
CO
DK
GUBRA.CO

0 Comments

Share your thoughts

FAQs

What is Gubra AS stock price today?▼
The current price of PI3.XETRA is €40.00 EUR — it has increased by +1.42% in the past 24 hours. Watch Gubra AS stock price performance more closely on the chart.
What is Gubra AS stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XETRA Stock Exchange exchange Gubra AS stocks are traded under the ticker PI3.XETRA.
What is Gubra AS market cap?▼
Today Gubra AS has the market capitalization of 657.44M
When is the next Gubra AS earnings date?▼
Gubra AS is going to release the next earnings report on March 3, 2027.
What were Gubra AS earnings last quarter?▼
PI3.XETRA earnings for the last quarter are -0.87 EUR per share, whereas the estimation was -0.67 EUR resulting in a -30.45% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Gubra AS revenue for the last year?▼
Gubra AS revenue for the last year amounts to 353.41M EUR.
What is Gubra AS net income for the last year?▼
PI3.XETRA net income for the last year is 226.61M EUR.
Does Gubra AS pay dividends?▼
Yes, PI3.XETRA dividends are paid en. The last dividend per share was 8.2 . As of today, Dividend Yield (FWD)% is 0%.
How many employees does Gubra AS have?▼
As of November 4, 2026, the company has 330 employees.
In which sector is Gubra AS located?▼
Gubra AS operates in the Health & Wellness sector.
When did Gubra AS complete a stock split?▼
Gubra AS has not had any recent stock splits.
Where is Gubra AS headquartered?▼
Gubra AS is headquartered in Horsholm, Denmark.